Evidence map›Paper›PMID 36723667›Full record

ArticleOrganic letters2023

Synthesis of

Cheng-Yi Chen, Zhichao Lu, Thomas Scattolin, Chengsheng Chen, Yonghong Gan, Mark McLaughlin

Open access · hybridAbstract read
In one paragraph

Article in Organic letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. The current landscape of using direct inhibitors to target KRASExperimental hematology & oncology · 2023
    Review
  8. Beilstein journal of organic chemistry · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Cheng-Yi ChenChemical Process R&D, Mirati Therapeutics, San Diego, California 92121, United States.ORCID 0000-0001-7666-3087
Zhichao LuChemical Process R&D, Mirati Therapeutics, San Diego, California 92121, United States.
Thomas ScattolinChemical Process R&D, Mirati Therapeutics, San Diego, California 92121, United States.ORCID 0000-0002-2950-2456
Chengsheng ChenChemical Process R&D, Mirati Therapeutics, San Diego, California 92121, United States.
Yonghong GanChemical Process R&D, Mirati Therapeutics, San Diego, California 92121, United States.
Mark McLaughlinChemical Process R&D, Mirati Therapeutics, San Diego, California 92121, United States.
Mirati Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A concise, transition-metal and protection-free synthesis of

Indexed as

NeoplasmsProto-Oncogene Proteins p21(ras)AcetonitrilesHumansMutationPiperazinesPyrimidinesAcetonitrilesadagrasibKRAS protein, humanPiperazinesProto-Oncogene Proteins p21(ras)Pyrimidines

Identifiers

PMID36723667
PMCPMC9942190
OpenAlexW4318754021

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.